Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People In Brief

This article was originally published in The Gray Sheet

Executive Summary

Kennedy rises at Viking: John "Jed" Kennedy is the new CEO of 2D and 3D visualization system manufacturer Viking Systems, effective Jan. 4. Kennedy has been president and chief operating officer at the company since October 2007 and was president of Viking's Vision Systems Group prior to that. Kennedy has also worked at Vista Medical and Smith & Nephew

You may also be interested in...



ev3 Expands Neurovascular Division With Acquisition Of Chestnut

ev3 is expanding its neurovascular division, already the fastest-growing segment of the company, by buying Chestnut Medical Technologies for $75 million up-front and up to $75 million in milestone payments, the companies announced June 2

Medtronic Catapults Into Transcatheter Valve Market With Billion-Dollar Buys

Medtronic will enter the high-growth, minimally invasive aortic heart valve market through two acquisitions worth more than $1 billion

Regeneration/Tutogen Merger Creates Broad Biologic Implant Portfolio

Regeneration Technologies Inc. will maintain both the BioCleanse and Tutoplast tissue sterilization processes for making biologic implants following its acquisition of Tutogen in a $263 million stock-swap deal, announced Nov. 13

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028337

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel